Davis Polk advised the underwriters in connection with the SEC-registered offering by BioXcel Therapeutics, Inc. of 2,300,000 shares of its common stock. The common stock is listed on the Nasdaq Capital Market under the symbol “BTAI.”
Based in New Haven, Connecticut, BioXcel Therapeutics is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence-based approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology.
The Davis Polk corporate team included partners Deanna L. Kirkpatrick and Yasin Keshvargar, counsel Jeffrey S. Ramsay and associates Angela Park and Sana Bargach. The intellectual property and technology transactions team included partner David R. Bauer and associate Jay Frankel. The tax team included partner Patrick E. Sigmon. The environmental team included counsel David A. Zilberberg. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.